[EN] ARGINASE INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'ARGINASE ET PROCÉDÉS D'UTILISATION
申请人:MERCK SHARP & DOHME
公开号:WO2019177873A1
公开(公告)日:2019-09-19
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
Concise synthesis of both diastereomers of 3-hydroxy-l-arginine
作者:Anke Lemke、Martin Büschleb、Christian Ducho
DOI:10.1016/j.tet.2009.10.102
日期:2010.1
of the non-proteinogenic amino acid capreomycidine and possibly also of its epimerepicapreomycidine. The novel concise synthesis of 3-hydroxy-l-arginine presented here allows the efficient preparation of both 3-epimers of this β-hydroxy amino acid. It also offers the potential to obtain suitably isotope-labelled derivatives for the elucidation of epicapreomycidine assembly in the biosynthesis of complex
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
作者:Min Lu、Hongjun Zhang、Derun Li、Matthew Childers、Qinglin Pu、Rachel L. Palte、Symon Gathiaka、Thomas W. Lyons、Anandan Palani、Peter W. Fan、Peter Spacciapoli、J. Richard Miller、Hyelim Cho、Mangeng Cheng、Kalyan Chakravarthy、Jennifer O’Neil、Padmanabhan Eangoor、Adam Beard、Hai-Young Kim、Josep Saurí、Hakan Gunaydin、David L. Sloman、Phieng Siliphaivanh、Jared Cumming、Christian Fischer
DOI:10.1021/acsmedchemlett.1c00195
日期:2021.9.9
ARGINASE INHIBITORS AND METHODS OF USE
申请人:Merck Sharp & Dohme Corp.
公开号:US20210040127A1
公开(公告)日:2021-02-11
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.